Wednesday, June 10, 2026

biotech Β· Fabry Disease (X-linked lysosomal storage disease). Β· Kidney Transplant Rejection Β· SGMO

SANGAMO THERAPEUTICS

SANGAMO THERAPEUTICS clinical programs β€” 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

7000 Marina Blvd, Brisbane, California 94005, US HQ
1995 Founded
266 Employees
Public company Type
SGMO Β· NYSE Ticker
Company details
Status
Public
HQ
7000 Marina Blvd, Brisbane, California 94005, US
Founded
1995
Employees
266
Programs
25
Drugs
14
Patents
192
Intelligence Β· Clinical Programs

SANGAMO THERAPEUTICS projects

17 ClinicalTrials.gov programs sponsored by SANGAMO THERAPEUTICS.

SANGAMO THERAPEUTICS has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial
  2. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial
  3. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial
  4. Plerixafor

    SANGAMO THERAPEUTICS, INC

    Sickle Cell Disease

    phase 2 mab completed

    1 trial
  5. SB-318

    SANGAMO THERAPEUTICS, INC

    MPS I

    phase 2 mab terminated

    1 trial
  6. SB-509

    SANGAMO THERAPEUTICS, INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial
  7. SB-509

    SANGAMO THERAPEUTICS, INC

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials
  8. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 2 gene therapy completed

    2 trials
  9. SB-728mR-T

    SANGAMO THERAPEUTICS, INC

    Human Immunodeficiency Virus (HIV)

    phase 2 gene therapy completed

    1 trial
  10. SB-913

    SANGAMO THERAPEUTICS, INC

    Mucopolysaccharidosis II

    phase 2 mab terminated

    1 trial
  11. ST-400 Investigational product

    SANGAMO THERAPEUTICS, INC

    Transfusion Dependent Beta-thalassemia

    phase 2 gene therapy completed

    1 trial
  12. ST-503

    SANGAMO THERAPEUTICS, INC

    Chronic Neuropathic Pain

    phase 2 gene therapy active

    1 trial
  13. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial
  14. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease

    phase 2 mab completed

    1 trial
  15. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial
  16. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 2 mab active

    1 trial
  17. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does SANGAMO THERAPEUTICS have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.